Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNP023 dose-ranging study in primary IgA nephropathy
NL-OMON50202Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Iptacopan in IgA nephropathy (IgAN) (5 arms), sponsored by Novartis. Primary endpoint: Dose-response effect on proteinuria at Day 90. Started Sep 2018; status: completed.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NL-OMON50202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50202.